(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of -29.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.25%.
Spero Therapeutics's revenue in 2024 is $110,978,000.On average, 1 Wall Street analysts forecast SPRO's revenue for 2024 to be $2,114,656,650, with the lowest SPRO revenue forecast at $2,114,656,650, and the highest SPRO revenue forecast at $2,114,656,650.
In 2025, SPRO is forecast to generate $2,996,258,465 in revenue, with the lowest revenue forecast at $2,996,258,465 and the highest revenue forecast at $2,996,258,465.